AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 11 min read$CRNX

Nichols Weston sold (to issuer) $1.9M of CRNX

Nichols Weston sold (to issuer) 22,225 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($1.89M total) across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · Nichols Weston
Published Sep 1, 2026, 9:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CRNX
Bearish
medium confidence
Mentioned
$CRNX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRNXBearishLow
01

Why it matters

Director's complete exit may affect market perception of CRNX.

02

Market read

Direct insider sell provides new data point for traders monitoring CRNX.

03

What to watch

No accompanying corporate news; sale may be unrelated to company performance.

Relevance 6/10Novelty 5/10Timing: filing date 2026-09-01

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CRNXBearishMedium confidence
Context

Director Nichols Weston sold 22,225 shares for $1.889M on 2026-09-01, reducing his stake to zero.

Expected impact

Possible short-term downside pressure.

Evidence & confidence

Director-level insider sale of nearly $2M is material for a micro‑cap biotech and could influence investor sentiment.

Market effects

Sector

May raise concerns for biotech sector insiders.

Regional

Limited to US biotech investors.

Global

Low

Counterpoint

What could challenge this read

Insider sale could be routine liquidity event, not a negative signal.

Key entities

  • Director
    Nichols Weston

    Insider who sold shares.

  • Company
    Crinetics Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRNX insider trading history →

Related articles

SEP 2
$VRTXHighAI 9/10

Vertex Completes $10 Billion Acquisition Of Crinetics Pharmaceuticals

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

pulse2.com2 min
SEP 2
$CRNXLowAI 9/10

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

simplywall.st2 min